Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy-Reference-Cited by-同舟云学术

Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy

Published:2017-06-06 Issue:33 Volume:8 Page:55715-55730
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Ding Xiao-Xiao¹,Zhu Qing-Ge¹,Zhang Shi-Ming¹,Guan Lei¹,Li Ting¹,Zhang Lei¹,Wang Shi-Yang²,Ren Wan-Li²,Chen Xue-Mei¹,Zhao Jing¹,Lin Song¹,Liu Zhi-Zhen¹,Bai Yan-Xia²,He Bing¹,Zhang Hu-Qin¹

Affiliation:

1. The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi’an Jiaotong University, Xi’an 710049, P. R. China

2. Department of Otorhinolaryngology - Head and Neck Surgery, The First Affiliated Hospital, Jiaotong University, Shaanxi 710061, P. R. China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sensitization of hepatocellular carcinoma cells to HDACi is regulated through hsa-miR-342-5p/CFL1;Cancer Cell International;2024-08-16

2. Construction and validation of prognostic signature for transcription factors regulating T cell exhaustion in hepatocellular carcinoma;Medicine;2024-07-05

3. Characterization of tumor evolution by functional clonality and phylogenetics in hepatocellular carcinoma;Communications Biology;2024-03-29

4. Emerging role of molecular diagnosis and personalized therapy for hepatocellular carcinoma;iLIVER;2024-03

5. Linoleate-pazopanib conjugation as active pharmacological ingredient to abolish hepatocellular carcinoma growth;Frontiers in Pharmacology;2024-01-16